|
Federal Register Notices > Notices of Registration - 2000 > Glaxo Wellcome Inc. Notices of Registration - 2000[Federal Register: November 28, 2000 (Volume 65,
Number 229)] DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated September 1, 2000, and published in
the Federal Register on September 25, 2000, (65 FR 57621), Glaxo Wellcome
Inc., Attn: Jeffrey A. Weiss, 1011 North Avendell Avenue, P.O. Box 1217,
Zebulon, North Carolina 27597-2309, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as an importer The remifentanil is being imported for the production of Ultiva dosage forms and for research and new product development. No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Glaxo Wellcome Inc. to import remifentanil is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Glaxo Wellcome Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to section 1008(a) of the Controlled Substances Import and Export Act and in accordance with title 21, Code of Federal Regulations, section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above. Dated: November 7, 2000. John H. King, [FR Doc. 00-30291 Filed 11-27-00; 8:45 am]
Registration
Support
|
